159 related articles for article (PubMed ID: 35690308)
1. A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking.
Huang Y; Dai X; Guan Z; Liu D; Ren L; Chen M; Zeng Z; Jiang J; Luo Y; He Y; Huang M; Zhao C
Int J Pharm; 2022 Jun; 622():121897. PubMed ID: 35690308
[TBL] [Abstract][Full Text] [Related]
2. A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer.
Fang W; Wang J; Ma X; Shao N; Ye K; Zhang D; Shi C; Luo L
Int J Nanomedicine; 2023; 18():6001-6019. PubMed ID: 37901361
[TBL] [Abstract][Full Text] [Related]
3. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
5. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
[TBL] [Abstract][Full Text] [Related]
6. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
9. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
10. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional Novel Nanoplatform for Effective Synergistic Chemo-Photodynamic Therapy of Breast Cancer by Enhancing DNA Damage and Disruptions of Its Reparation.
Huang Z; Xian T; Meng X; Hu H; Gao L; Huang J; Yang D; Ou K; Wang B; Zhang Y
Molecules; 2023 Oct; 28(19):. PubMed ID: 37836815
[TBL] [Abstract][Full Text] [Related]
12. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
13. DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
Shi Y; Jin J; Wang X; Ji W; Guan X
Neoplasia; 2019 Jun; 21(6):533-544. PubMed ID: 31029033
[TBL] [Abstract][Full Text] [Related]
14. Dual-target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP-ribose) polymerase (PARP-1) and enhancing DNA damage.
Li R; Zhao W; Jin C; Xiong H
Bioorg Chem; 2023 Apr; 133():106354. PubMed ID: 36720184
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
Xie XF; Wu NQ; Wu JF; Zhang GL; Guo JF; Chen XL; Du CW
Cancer Lett; 2022 Dec; 551():215944. PubMed ID: 36209974
[TBL] [Abstract][Full Text] [Related]
16. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
17. Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
Guney Eskiler G; Ozman Z; Haciefendi A; Cansaran-Duman D
Naunyn Schmiedebergs Arch Pharmacol; 2023 May; 396(5):1031-1041. PubMed ID: 36598514
[TBL] [Abstract][Full Text] [Related]
18. FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair.
Wang SP; Wu SQ; Huang SH; Tang YX; Meng LQ; Liu F; Zhu QH; Xu YG
Cell Death Dis; 2021 Dec; 12(12):1138. PubMed ID: 34880209
[TBL] [Abstract][Full Text] [Related]
19. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
Zhang J; Yang C; Tang P; Chen J; Zhang D; Li Y; Yang G; Liu Y; Zhang Y; Wang Y; Liu J; Ouyang L
J Med Chem; 2022 May; 65(9):6803-6825. PubMed ID: 35442700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
